Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status ...

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF ...

In some parts of the world, record numbers of people are being diagnosed with attention deficit hyperactivity disorder (ADHD) ...

Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedomNew X-TOLE OLE data analysis supports the ability to ...

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced new data presented on its lead investigational ...

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care ...

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line1 ...

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of ...

Blood tests for Alzheimer’s disease are rapidly moving into clinics, promising earlier and easier detection of brain changes ...

BGB-16673 showed high overall response rates in relapsed/refractory CLL/SLL, with a notable 94.4% response at the 200-mg dose level. Safety analysis revealed that 95.6% of patients experienced ...

Rusfertide was generally well-tolerated through 52 Weeks of treatment. The most common treatment-emergent adverse events (AE) in rusfertide-treated patients were injection site reactions (47.4%), ...

The analysis of an exploratory composite endpoint revealed that early treatment with AP-101 prolonged survival and delayed ventilatory support in comparison to study participants ...